File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Ethnicity is a factor to be considered before dose planning in ovarian cancer patients to be treated with topotecan

TitleEthnicity is a factor to be considered before dose planning in ovarian cancer patients to be treated with topotecan
Authors
KeywordsChinese
Myelotoxicity
Neutropenia
Topotecan
Issue Date2006
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.ijgc.net/
Citation
International Journal Of Gynecological Cancer, 2006, v. 16 n. 1, p. 135-139 How to Cite?
AbstractThe objective of this study was to determine the efficacy and toxicity of topotecan in Chinese patients with ovarian cancer. A retrospective analysis on recurrent ovarian cancer patients receiving topotecan 1.25 mg/m 2 daily for 5 consecutive days on a 21-day cycle from 1997 to 2002 was conducted. The patients included were all treated with at least two cycles of topotecan. The patient characteristics were compared in relation to their toxicity profile and their response to treatment. Response was evaluated by physical findings, imaging techniques, and serum CA125 level. A total of 60 patients were included in the study. All patients were evaluable for response and toxicities. A total of 361 cycles were given (median, 5 per patient; range 2-15). The major toxicity was neutropenia, which was grade 4 in 45.0% of the patients and 10.2% of the cycles. Age was the only covariate predicting the occurrence of grade 4 neutropenia (logistic regression P= 0.046, CI 1.01-1.12). Neutropenic fever occurred in 8.3% of the patients. Eighteen (30%) patients were required to delay their chemotherapy and 11 (18.3%) required dose reduction. Nonhematologic toxicities were mild. The overall response rate was 21.6%, with eight (13.3%) complete responses and five (8.3%) partial responses. The median duration of response and median time to progression were 11 and 5 months, respectively. The median survival was 14 months. Topotecan 1.25 mg/m 2 in a five-times-daily schedule was well tolerated in a cohort of Chinese patients. Myelotoxicity was the most important side effect in our study, but the incidence is much lower than that reported in other studies. Age was an independent factor predicting the occurrence of grade 4 neutropenia. © 2006, IGCS.
Persistent Identifierhttp://hdl.handle.net/10722/87326
ISSN
2015 Impact Factor: 2.116
2015 SCImago Journal Rankings: 0.830
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTam, KFen_HK
dc.contributor.authorChan, YMen_HK
dc.contributor.authorNg, TYen_HK
dc.contributor.authorWong, LCen_HK
dc.contributor.authorNgan, HYSen_HK
dc.date.accessioned2010-09-06T09:28:14Z-
dc.date.available2010-09-06T09:28:14Z-
dc.date.issued2006en_HK
dc.identifier.citationInternational Journal Of Gynecological Cancer, 2006, v. 16 n. 1, p. 135-139en_HK
dc.identifier.issn1048-891Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/87326-
dc.description.abstractThe objective of this study was to determine the efficacy and toxicity of topotecan in Chinese patients with ovarian cancer. A retrospective analysis on recurrent ovarian cancer patients receiving topotecan 1.25 mg/m 2 daily for 5 consecutive days on a 21-day cycle from 1997 to 2002 was conducted. The patients included were all treated with at least two cycles of topotecan. The patient characteristics were compared in relation to their toxicity profile and their response to treatment. Response was evaluated by physical findings, imaging techniques, and serum CA125 level. A total of 60 patients were included in the study. All patients were evaluable for response and toxicities. A total of 361 cycles were given (median, 5 per patient; range 2-15). The major toxicity was neutropenia, which was grade 4 in 45.0% of the patients and 10.2% of the cycles. Age was the only covariate predicting the occurrence of grade 4 neutropenia (logistic regression P= 0.046, CI 1.01-1.12). Neutropenic fever occurred in 8.3% of the patients. Eighteen (30%) patients were required to delay their chemotherapy and 11 (18.3%) required dose reduction. Nonhematologic toxicities were mild. The overall response rate was 21.6%, with eight (13.3%) complete responses and five (8.3%) partial responses. The median duration of response and median time to progression were 11 and 5 months, respectively. The median survival was 14 months. Topotecan 1.25 mg/m 2 in a five-times-daily schedule was well tolerated in a cohort of Chinese patients. Myelotoxicity was the most important side effect in our study, but the incidence is much lower than that reported in other studies. Age was an independent factor predicting the occurrence of grade 4 neutropenia. © 2006, IGCS.en_HK
dc.languageengen_HK
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.ijgc.net/en_HK
dc.relation.ispartofInternational Journal of Gynecological Canceren_HK
dc.subjectChineseen_HK
dc.subjectMyelotoxicityen_HK
dc.subjectNeutropeniaen_HK
dc.subjectTopotecanen_HK
dc.titleEthnicity is a factor to be considered before dose planning in ovarian cancer patients to be treated with topotecanen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1048-891X&volume=16&issue=1&spage=135&epage=139&date=2006&atitle=Ethnicity+is+a+factor+to+be+considered+before+dose+planning+in+ovarian+cancer+patients+to+be+treated+with+topotecanen_HK
dc.identifier.emailNgan, HYS:hysngan@hkucc.hku.hken_HK
dc.identifier.authorityNgan, HYS=rp00346en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1525-1438.2006.00295.xen_HK
dc.identifier.pmid16445623-
dc.identifier.scopuseid_2-s2.0-33645369153en_HK
dc.identifier.hkuros117250en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33645369153&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume16en_HK
dc.identifier.issue1en_HK
dc.identifier.spage135en_HK
dc.identifier.epage139en_HK
dc.identifier.isiWOS:000234800100022-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridTam, KF=35622901400en_HK
dc.identifier.scopusauthoridChan, YM=7403676661en_HK
dc.identifier.scopusauthoridNg, TY=7402229853en_HK
dc.identifier.scopusauthoridWong, LC=7402092003en_HK
dc.identifier.scopusauthoridNgan, HYS=34571944100en_HK
dc.identifier.citeulike479465-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats